FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its sponsorship of Master Hub LatAm 2026, described by organizers as the most important aesthetic medicine and facial rejuvenation congress in Latin America. Master Hub LatAm 2026

FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an operational expansion into Colombia, adding local commercial infrastructure and building physician and medical-provider relationships across the market. The Colombia expansion follows Cellgenic’s recent moves into Peru

FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the establishment of permanent operations and offices in Brazil. Brazil represents one of Latin America’s largest healthcare and aesthetic-medicine markets, and Cellgenic said the buildout includes local

FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its expansion into Peru through the establishment of local operations and exclusive representation arrangements. The Peru launch extends Cellgenic’s Latin American commercial network, which the Company has

FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an expansion of its flagship laboratory facilities in Cancun, Mexico, adding two ISO 7-classified clean rooms to the Company’s existing laboratory infrastructure. The additional capacity is intended

FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced a next-generation peptide delivery portfolio featuring combination peptide pens and intranasal delivery formats, developed in response to international physician and market demand for more convenient and diversified

FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the introduction of a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets, including Latin America, the Middle East, Europe, and Southeast Asia, subject to applicable

FOR IMMEDIATE RELEASE MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the launch of a Natural Killer (NK) cell product line for permitted markets outside the United States, with an initial commercial focus on Latin America and Southeast

Xeno-Free Biologics Facility in Cancún, Now Producing and Distributing Six Product Lines to International Markets COFEPRIS-Guided Laboratory Actively Shipping Exosomes, MSCs, NK Cells, and Allogeneic Fibroblasts as Company Advances Authorized Distributor Program and 2026 Pipeline Expansion Including Peptide Formulations, Secretome, and Private-Label Manufacturing LAS VEGAS, NV / July 14th, 2026 / Regenerative Medical Technologies Group, Inc. (the

Cellgenic launches regulated commercial operations in Argentina, creating a platform for biologics distribution, physician education, and regional expansion. BOCA RATON, FL — April 26, 2026 — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”), through its wholly owned subsidiary Global Stem Cells Group and its commercial division Cellgenic, today announced a major

Miami, FL / Global — March 22nd, 2026 Global Stem Cells Group, operating under RMTG, today announced the official launch of the ISSCA Mobile App, a next-generation digital platform designed to unify physician education, clinical collaboration, and professional networking across the rapidly growing regenerative and longevity medicine sectors. The app has been developed by ISSCA

Miami, FL / Global — February 12, 2026 Global Stem Cells Group, a publicly traded leader in regenerative medicine and advanced cellular therapies, today announced the official launch of ISSCA AI™ Clinical Intelligence Platform, a next-generation artificial intelligence system developed by its education and innovation division, ISSCA (International Society for Stem Cell Application). This milestone